New Treatment for Plaque Psoriasis Approved in Europe – Drug for nerve pain boosts high for opioid abusers.

1987_GraphicImage_060915_GrAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

New Treatment for Plaque Psoriasis Approved in Europe – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Almirall has received European Commission approval for its plaque psoriasis treatment tildrakizumab (Ilumetri), Sun Pharma announced in a press release.

Tildrakizumab, a humanized high-affinity anti-IL-23p19 monoclonal antibody, is indicated for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. Sun Pharma out-licensed tildrakizumab to Almirall for the development and commercialization of the product for psoriasis in Europe.

The drug’s European approval is based on data from the reSURFACE 1 and 3 phase 3 clinical trials, which included 1800 patients from more than 200 clinical sites worldwide and evaluated tildrakizumab’s safety and efficacy.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.